Payment & Shipping Terms:
|Assay:||99% Min||Character:||White Crystal Powder|
|Centigrade Assay:||≥99.5%||Packing:||1Kg/foil Bag Or As Required|
natural weight loss powder,
steroid fat burner
My website: http://www.roidsonlinecn.com/
Rimonabant A 281 Sr 141716 168273-06-1 weight loss Obesity Smoking cessation Addiction behaviors
Alias:Acompltan;A 281;Sr 141716;5-(4-Chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-piperidinopyrazole-3-carboxamide
MP: 230 ~ 240
Rimonabant is a weight loss drug, can significantly reduce weight, reduce waist circumference and reduce risk factors for cardiovascular disease, but also can improve blood lipids and insulin resistance and metabolic syndrome, especially for the presence of clinical obesity or heart disease people at risk.
Rimonabant as a new weight loss drug, can also be used to quit smoking.
Not only lose weight, but also lower blood pressure, cholesterol and blood sugar, clinical study found that subjects taking one to two months later, the weight can be reduced on average six to eight kilograms.
|Synonyms:||ACOMPLIA;RIMONABANT;RIMONABANT(ACOMPLIA,SR141716);5-(4-Chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-piperidinopyrazole-3-carboxamide;1H-Pyrazole-3-carboxamide, 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-1-piperidinyl-;5-(4-Chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-1-piperidinyl-1H-pyrazole-3-carboxamide;A 281;Sr 141716|
(Weight loss series)
|Rimonabant CAS NO. 168273-06-1
Synephrine CAS NO. 94-07-5
Theobromine CAS NO.83-67-0
L(-)-Carnitine CAS NO. 541-15-1
L-Thyroxine(T4) CAS NO.51-48-9
Calcium Pyruvate CAS NO.52009-14-0
1,3-DMAA HCl CAS NO.13803-74-2
Rimonabant (also known as SR141716; trade name Acomplia) is an anorectic antiobesity drug that has been withdrawn from the market due to potentially serious side effects. It was approved for use in Europe and other countries, but never approved in the United States. Rimonabant is an inverse agonist for the cannabinoid receptor CB1.It has also been shown to be a μ-opioid receptor antagonist (possibly the contributing factor in its reported dysphoric qualities). Its main effect is reduction in appetite.
Rimonabant may also be found to be effective in assisting some smokers to quit smoking. Sanofi is currently conducting studies to determine the possible value of rimonabant in smoking-cessation therapy. The Studies with Rimonabant and Tobacco Use (STRATUS) program involves more than 6,000 subjects. STRATUS is designed to explore two smoking-related therapies: first, to use rimonabant directly to aid in smoking cessation; second, to help prevent weight gain in former smokers. Initial results apparently suggest rimonabant is effective for both uses. However, the FDA has explicitly stated to Sanofi that, without additional studies, rimonabant cannot be approved in the United States for smoking cessation therapy
Safe Packaging & Fastest Delivery: